Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
More Reading from MarketBeat Media The 3 Penny Stocks You Swore You'd Never Buy (But You'll Check Anyway)Written by Chris Markoch. Date Posted: 1/18/2026. 
In Brief - Vaxart is a clinical-stage biotech developing oral vaccines that could transform global immunization if its platform proves effective.
- Microvision develops cost-effective lidar technology for autonomous vehicles, with upside tied to industry adoption and potential partnerships.
- Datavault AI focuses on monetizing digital data through AI and blockchain tools, offering speculative exposure to the emerging data-as-an-asset theme.
Penny stocks attract speculative investors seeking high-risk, high-reward opportunities — companies with disruptive technologies, participation in an emerging trend, or compelling turnaround stories. Many of these firms will never scale, but if even one succeeds, investors can see outsized returns. For investors who prefer a data-driven starting point, MarketBeat offers a tool listing the 100 Most Popular Penny Stocks, ranked by the number of MarketBeat subscribers following each company. While popularity isn't a guarantee of success, it can provide additional conviction when researching a trade. Wall Street veteran reveals #1 investment trend of 2026 (not AI)
Will you potentially make money or lose money in the U.S. stock market in 2026? According to the 50-year Wall Street legend who invented one of Wall Street's most popular buying and selling indicators – the answer has nothing to do with AI, quantum computing, or cryptos. Instead, it all comes down to the #1 stock he recommends you BUY now… And the #1 stock he recommends you SELL now. Some investors use a $5 cutoff for penny stocks, but the screener used here follows the traditional definition — stocks trading below $1. These securities are highly volatile; conduct your own research and ensure your positions match your risk tolerance before investing. Vaxart: A Potential Game-Changer for Global Immunization Efforts Vaxart Inc. (NASDAQ: VXRT) is a clinical-stage biotechnology company developing oral vaccines for infectious diseases, including influenza, norovirus and COVID-19. Unlike injectable vaccines, Vaxart's tablet-based platform aims to simplify distribution and improve global accessibility. The bull case centers on that innovative delivery approach. If Vaxart can secure FDA approval and scale production, its oral vaccines could reduce logistical barriers to mass immunization and create significant licensing opportunities. Positive trial results or a commercial partnership could materially change sentiment and valuation, given the stock's current low base. Clinical risk is the primary challenge: Vaxart has not yet brought a product to market, and vaccine development is costly and unpredictable. Competition from larger players with deeper R&D budgets also constrains visibility. At present, Vaxart is more of a long-term, speculative bet on platform validation than a near-term profitability story. MarketBeat analyst ratings show only a single analyst covering VXRT — not uncommon for microcap biotech, but a signal to use caution. The stock has roughly 18% institutional ownership and about 2% short interest, which may help limit some downside volatility. Microvision: Developing Cost-Effective LiDAR Units For Autonomous Driving Microvision Inc. (NASDAQ: MVIS) develops LiDAR (light detection and ranging) sensors for autonomous vehicles, smart infrastructure and industrial sensing. Its hardware and software enable precise 3D mapping needed for self-driving and advanced driver-assistance systems (ADAS). Microvision focuses on compact, cost-effective LiDAR units that could appeal to automakers seeking scalable sensor solutions. The bull case depends on continued progress toward vehicle automation and potential partnerships with major automakers. If Microvision can demonstrate performance or cost advantages, it could win supply agreements or licensing deals that boost revenue visibility. The technology also has potential applications in robotics and smart cities, adding optionality to the growth story. However, Microvision competes with well-funded LiDAR players such as Luminar (NASDAQ: LAZR), Innoviz (NASDAQ: INVZ) and Ouster (NYSE: OUST). The path to profitability is uncertain, and repeated delays in LiDAR adoption have frustrated investors. MVIS is covered by three analysts and carries a consensus price target of $2.50 — about a 169% premium to its Jan. 15 closing price. Yet it has relatively low institutional ownership (around 30%) and high short interest (about 21%), which implies elevated volatility for long-term investors. Datavault AI: Trying to Democratize Data Ownership Datavault AI Inc. (NASDAQ: DVLT) operates at the intersection of artificial intelligence, data monetization and digital asset management. The company helps organizations convert raw data into tradable, revenue-generating assets through its patented Datavault platform. By combining AI, blockchain and analytics, Datavault AI aims to democratize data ownership and unlock monetization opportunities that traditional systems may overlook. The bullish thesis rests on a niche focus and scalability potential. As data becomes more valuable, businesses — and individuals — are seeking ways to safely monetize digital information. Datavault's platform could benefit from wider AI adoption and growing awareness of data sovereignty. Early traction or strategic partnerships could catalyze investor confidence. However, Datavault AI operates in a highly experimental space. Its business model is still evolving, and its path to meaningful revenue growth is unproven. Institutions own less than 1% of the stock, and short interest exceeds 16% at the time of writing. DVLT should be considered a long-term, speculative position based on belief in data-as-an-asset innovation rather than near-term earnings potential.
| 
